Table 2 of Teper, Mol Vis 2010; 16:2598-2604.

Table 2. Study population characteristics.

    CFH Y402H ARMS2 A69S
Genotype All CC CT TT TT GT GG
Genotype frequency - 28 (31.1%) 47 (52.2%) 15 (16.7%) 26 (28.9%) 33 (36.7%) 31 (34.4%)
Lesion area 15.64 17.82 14.75 14.38 15.31 16.81 14.68
[mm2] ±10.63 ±13.22 ±10.26 ±7.16 ±11.88 ±10.0 ±10.4
Kruskal–Wallis test H (2, n=90)=0.6011253 p=0.74 H (2, n=90)=1.366674 p=0.505
Type of CNV 31:30 11:10:7 14:16:17 6:4:5 12:9:13 12:10:11 7:11:5
pdc:mc:oc 29            
Kruskal–Wallis test H (2, n=90)=0.6248223 p=0.732 H (2, n=90)=4.495667 p=0.106
BCVA 41.79 40.28 43.51 39.2 41.31 38.79 45.39
[letters] ±14.52 ±15.62 ±14.19 ±13.66 ±16.47 ±13.7 ±13.26
Kruskal–Wallis test H (2, n=90)=1.164551 p=0.559 H (2, n=90)=3.937457 p=0.14
BCVA after 12 months 46.23 42.32 49.06 44.67 42.65 43.12 52.55
[letters] ±16.54 ±16.77 ±15.78 ±17.82 ±17.09 ±16.93 ±14.13
   (4.44±8.12) (2.04±6.01) (5.55 (5.47 (1.35 (4.33 (7.16
       ±9.53) ±5.85) ±8.87) ±8.92) ±5.39)
   p<0.01 p=0.04 p<0.01 p<0.01 p=0.5 p<0.01 p<0.01
CSRT [µm] 331.95±99.05 333.71±85.53 332.85 325.87 312.85 338.18 341.35
       ±100.22 ±123.31 ±103.54 ±89.69 ±105.55
Kruskal–Wallis test H (2, n=90)=1.164551 p=0.559 H (2, n=90)=3.937457 p=0.14
CSRT after 12 months [µm] 228.32 234.61 231.36 207.07 223.58 206.09 255.97
  ±72.27 ±80.08 ±71.59 ±58.35 ±82.03 ±46.69 ±78.80
  (103.63±94.7) (99.11 (101.49 (118.8 (89.27 (132.09 (85.39 ±91.98)
  p<0.01 ±83.49) ±92.87) ±122.19) ±100.66) ±88.16) p<0.01
    p<0.01 p<0.01 p<0.01 p<0.01 p<0.01
Injections 5.77±1.51 5.96±1.64 5.83±1.34 5.2±1.74 5.85±1.51 5.79±1.56 5.68±1.51

BCVA – best-corrected visual acuity, CNV – choroidal neovascularization (pdc-predominantly classic, mc-minimally classic, oc-occult), CSRT – central subfield retinal thickness

Teper, Mol Vis 2010; 16:2598-2604. http://www.molvis.org/molvis/v16/a278

©2010 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535